Syros Pharmaceuticals has discontinued enrollment in its SELECT-AML-1 Phase 2 trial for acute myeloid leukemia (AML), citing disappointing results. The company observed similar response rates between the experimental triplet regimen and the standard doublet regimen, leading to a low probability of success in the final analysis. Despite the setback, Syros continues to evaluate tamibarotene in combination with azacitidine in a Phase 3 trial for myelodysplastic syndrome. This news has caused SYRS stock to drop significantly.